FENC Stock Analysis: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$9.14
-0.84 (-8.42%)
▼
5d:
-8.32%
30d:
+37.44%
90d:
+11.46%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FENC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: FENC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.59
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.79
28.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $9.14, which is considered slightly high relative to its 30-day fair value range of $6.81 to $9.84. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.9) compared to its historical average (10.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is currently testing key support at $9.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.57 (+70.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is currently testing key support at $9.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.57 (+70.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.81 -
$9.84
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 70.4% below Wall St target ($15.57)
- CAUTION: Recommendation downgraded due to -8.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$6.81 -
$9.84
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.06
Resistance Level
$10.45
Current Trend
Sideways
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.90
Wall Street Target
$15.57
(+70.4%)
Revenue Growth (YoY)
72.6%
Profit Margin
-16.4%
Valuation Discount vs History
-4.8% cheaper
PE vs Historical
8.9 vs 10.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.8%
(market-implied from PE analysis)
1-Year Target
$8.70
(-5%)
2-Year Target
$8.28
(-9%)
3-Year Target
$7.89
(-14%)
3-Yr Target (if PE normalizes)
(PE: 9→10)
$9.12
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 236.6%)
$75.92
(+731%)
Base:
(SPY PE: 8.9, Growth: 236.6%)
$30.85
(+238%)
Bear:
(PE: 7.6, Growth: 236.6%)
$26.22
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.9 to 10.3
Stabilization Target:
$10.58
(+15.7%)
PE Expansion Potential:
+15.7%
Share & Embed Analysis
Last updated: June 03, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10946 shares
2026-04-01
Rosty Raykov
SELL
10349 shares
2026-02-02
Southpoint Capital Advis…
SELL
1000000 shares
2025-12-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$252 | 54 HOLD |
